Canaccord lowered the firm’s price target on SI-Bone to $22 from $27 and keeps a Buy rating on the shares. The firm thinks they can be in a prolonged period of execution as investments in the commercial infrastructure, new products, and reimbursement tailwinds translate to productivity gains and upside to estimates through 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SIBN:
- SI-Bone price target lowered to $25 from $30 at Cantor Fitzgerald
- SI-Bone reports Q3 EPS (25c), consensus (34c)
- SI-BONE, Inc. Reports Record Financial Results for the Third Quarter 2023 and Raises Annual Guidance
- Is SIBN a Buy, Before Earnings?
- SI-BONE To Present at Jefferies London Healthcare Conference on November 15, 2023
